Organization | Y-Mabs, Inc

Y-Mabs, Inc Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: New York NY United States (2014)

Organization Overview

First Clinical Trial

2014

NCT02307630

First Marketed Drug

2020

naxitamab

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Y-mAbs Therapeutics | Y-mAbs Therapeutics, Inc | Y-MABS THERAPEUTICS INC

Active Ingredients

Marketed Drugs (1)

naxitamab (2020)

Drugs in Phase 3 Trials (3)

131 i-omburtamab (5 trials)

irinotecan (Camptosar) (3 trials)

temozolomide (temodar) (3 trials)

Drugs in Phase 2 Trials (10)

177lu-dtpa-omburtamab (2 trials)

acetaminophen (tylenol) (1 trial)

bevacizumab (avastin) (1 trial)

dexamethasone (1 trial)

isotretinoin (accutane) (1 trial)

liothyronine (cytomel) (1 trial)

naxitamab (4 trials)

nivatrotamab (1 trial)

potassium iodide (thyro-block) (1 trial)

sargramostim (leukine) (2 trials)

Drugs in Phase 1 Trials (3)

cd33*cd3 bsab (1 trial)

cyclophosphamide (cytoxan) (1 trial)

gd2-sada (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Desmoplastic Small Round Cell Tumor (Phase 2)

Medulloblastoma (Phase 2)

Meningeal Carcinomatosis (Phase 3)

Neoplasm Metastasis (Phase 3)

Neoplasms, Second Primary (Phase 3)

Neuroblastoma (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 15
# of Trial APIs: 16